The Nordic Exchange welcomes Genovis to First North in Sweden

Trading in Genovis shares will commence today on First North in Sweden. Including Genovis, First North now comprises 64 companies in Sweden and Denmark.

Genovis AB is a life science provider company, which develops and markets a concept for delivering and studying the hereditary disposition of living cells. Genovis’ customers are life science companies and academic institutions developing new gene based drugs. Genovis was founded in 1999 and operates out of the IDEON Science Park in Lund, Sweden. “We warmly welcome Genovis to First North. Genovis is a valuable contribution to our Health Care sector and the twenty-eighth company to be listed on First North this year”, says Jenny Rosberg, President of Company Services. Mangold Fondkommission AB is Certified Adviser for Genovis. A round lot of shares in Genovis, whose short name is GENO B, amounts to 500 and the company is included in the Health Care sector.